Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis is breathing easier following a positive recommendation from U.S. FDA's Pulmonary-Allergy Drugs Advisory Committee Nov. 20 for approval of its bronchial test Aridol